ErythroMer - Nanoscale Bio-Synthetic Artificial Red Cell

Leveraging the Contractile Force of Platelets for Targeted Factor VIII Delivery in Hemophilia with Inhibitors

Survival Following Allogeneic Hematopoietic Cell Transplantation in High-Risk AML Patients Initially Treated with CPX-351 vs. Standard Cytarabine and Daunorubi

Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 CAR in Children and Young Adults with Relapsed/Refractory ALL

SUSTAIN Study: Assessing Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Feasibility Trial for Primary Stroke Prevention in Children with Sickle Cell Anemia in Nigeria (SPIN Trial)

Prospective Implementation of Multi-Disciplinary Obstetric Team Decreases the Mortality Rate of Pregnant Women with Sickle Cell Disease in Ghana

Determining the Incidence and Risk Factors for Central Venous Catheter Related Thrombosis in Children

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

A Miniaturized Microfluidic Dielectric Sensor for Point-of-Care Assessment of Blood Coagulation

Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Novelties and future directions in AML therapy

Chronic myeloid leukemia: First-line drug of choice; TKIs

Influencing B-cell Receptor Signaling; Results from studies with ibrutinib (PCYC-1102, 1103, RESONATE-2 Trial)

Summary of venetoclax therapy in CLL

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

COMFORT-I Study: Effects of Long-Term Ruxolitinib on Bone Marrow Morphology in Patients with Myelofibrosis

Subgroup Analysis from ENESTop: Treatment-Free Remission in Patients with CML in Chronic Phase According to Reasons for Switching from Imatinib to Nilotini

GALLIUM Study: Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance

Treatment options of CLL

Institute/Carolinas HealthCare System, Charlotte, US, Study results with daratumumab

Pooled OS Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials

New therapeutic approaches in CLL, special focus on venetoclax